soul trial oral semaglutide cardiovascular outcomes nejm 2025 results Michael Albert, MD on X: "🚨 25 mg delivers double-digit weight loss in OASIS-4 (Phase 3 trial) - Oral semaglutide reduces heart risks

p = 0.35, p = 0.42, and p = 0.45 for interaction, respectively, for CV death, nonfatal MI, and nonfatal stroke)

Patient education should emphasize the limited evidence base, experimental nature of treatment, and importance of ongoing monitoring

The resulting increase in GABA release helps restore the balance of excitatory and inhibitory neurotransmission by decreasing glutamate activity, promoting neuronal survival, and enhancing mitochondrial function

14 years of research and development, a total of 19 Chinese invention patents and 2 international invention patents have been declared, of which 7 Chinese invention patents and 8 software copyrights have been authorized